Omeros reports Q3 2026 results, CHMP negative opinion on narsoplimab in Europe
YARTEMLEA U.S. sales rose as the company outlined 2026-2027 trial starts for OMS1029, OMS527, and OncotoX-AML, while Novo's zaltenibart Phase 3 stays on track.
SEC filing
2 stories
YARTEMLEA U.S. sales rose as the company outlined 2026-2027 trial starts for OMS1029, OMS527, and OncotoX-AML, while Novo's zaltenibart Phase 3 stays on track.
SEC filing
The board's compensation committee awarded Gregory Demopulos an option for up to 500,000 shares that vests only if Omeros stock hits price targets from $25 to $40.
SEC filing